133 related articles for article (PubMed ID: 9932611)
1. Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide.
Michigami T; Nomizu M; Yamada Y; Dunstan C; Williams PJ; Munday GR; Yoneda T
Clin Exp Metastasis; 1998 Oct; 16(7):645-54. PubMed ID: 9932611
[TBL] [Abstract][Full Text] [Related]
2. The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice.
Yoshida N; Ishii E; Nomizu M; Yamada Y; Mohri S; Kinukawa N; Matsuzaki A; Oshima K; Hara T; Miyazaki S
Br J Cancer; 1999 Aug; 80(12):1898-904. PubMed ID: 10471037
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis, tumour growth and experimental metastasis of human fibrosarcoma cells HT1080 by a multimeric form of the laminin sequence Tyr-Ile-Gly-Ser-Arg (YIGSR).
Iwamoto Y; Nomizu M; Yamada Y; Ito Y; Tanaka K; Sugioka Y
Br J Cancer; 1996 Mar; 73(5):589-95. PubMed ID: 8605091
[TBL] [Abstract][Full Text] [Related]
4. Effect of Matrigel and laminin peptide YIGSR on tumor growth and metastasis.
Yamamura K; Kibbey MC; Jun SH; Kleinman HK
Semin Cancer Biol; 1993 Aug; 4(4):259-65. PubMed ID: 8400148
[TBL] [Abstract][Full Text] [Related]
5. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma.
Chesney J; Metz C; Bacher M; Peng T; Meinhardt A; Bucala R
Mol Med; 1999 Mar; 5(3):181-91. PubMed ID: 10404515
[TBL] [Abstract][Full Text] [Related]
6. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.
Weimar IS; Weijer K; van den Berk PC; Muller EJ; Miranda N; Bakker AQ; Heemskerk MH; Hekman A; de Gast GC; Gerritsen WR
Br J Cancer; 1999 Sep; 81(1):43-53. PubMed ID: 10487611
[TBL] [Abstract][Full Text] [Related]
7. Multimeric forms of Tyr-Ile-Gly-Ser-Arg (YIGSR) peptide enhance the inhibition of tumor growth and metastasis.
Nomizu M; Yamamura K; Kleinman HK; Yamada Y
Cancer Res; 1993 Aug; 53(15):3459-61. PubMed ID: 8339246
[TBL] [Abstract][Full Text] [Related]
8. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice.
Nakai M; Mundy GR; Williams PJ; Boyce B; Yoneda T
Cancer Res; 1992 Oct; 52(19):5395-9. PubMed ID: 1394144
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice.
Miyoshi T; Hirohata S; Ogawa H; Doi M; Obika M; Yonezawa T; Sado Y; Kusachi S; Kyo S; Kondo S; Shiratori Y; Hudson BG; Ninomiya Y
FASEB J; 2006 Sep; 20(11):1904-6. PubMed ID: 16877525
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.
Fridman R; Giaccone G; Kanemoto T; Martin GR; Gazdar AF; Mulshine JL
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6698-702. PubMed ID: 2168554
[TBL] [Abstract][Full Text] [Related]
11. Role of laminin in ovarian cancer tumor growth and metastasis via regulation of Mdm2 and Bcl-2 expression.
Yoshida Y; Hosokawa K; Dantes A; Kotsuji F; Kleinman HK; Amsterdam A
Int J Oncol; 2001 May; 18(5):913-21. PubMed ID: 11295035
[TBL] [Abstract][Full Text] [Related]
12. Synthetic cell-adhesive laminin peptide YIGSR conjugated with polyethylene glycol has improved antimetastatic activity due to a longer half-life in blood.
Kaneda Y; Yamamoto S; Kihira T; Tsutsumi Y; Nakagawa S; Miyake M; Kawasaki K; Mayumi T
Invasion Metastasis; 1995; 15(3-4):156-62. PubMed ID: 8621271
[TBL] [Abstract][Full Text] [Related]
13. [Biological activity of synthetic analogs of laminin active sequences: YIGSR, RGD, SIKVAV].
Hill-Bator A; Opolski A
Postepy Hig Med Dosw; 2002; 56(5):579-88. PubMed ID: 12587426
[TBL] [Abstract][Full Text] [Related]
14. Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases.
Sweeney TM; Kibbey MC; Zain M; Fridman R; Kleinman HK
Cancer Metastasis Rev; 1991 Oct; 10(3):245-54. PubMed ID: 1764767
[TBL] [Abstract][Full Text] [Related]
15. Liposomes modified with YIGSR peptide for tumor targeting.
Dubey PK; Singodia D; Vyas SP
J Drug Target; 2010 Jun; 18(5):373-80. PubMed ID: 20020817
[TBL] [Abstract][Full Text] [Related]
16. Polymeric nanospheres modified with YIGSR peptide for tumor targeting.
Dubey PK; Singodia D; Vyas SP
Drug Deliv; 2010; 17(7):541-51. PubMed ID: 20560774
[TBL] [Abstract][Full Text] [Related]
17. Inserting chromosome 18 into pancreatic cancer cells switches them to a dormant metastatic phenotype.
Lefter LP; Sunamura M; Furukawa T; Takeda K; Kotobuki N; Oshimura M; Matsuno S; Horii A
Clin Cancer Res; 2003 Oct; 9(13):5044-52. PubMed ID: 14581380
[TBL] [Abstract][Full Text] [Related]
18. Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo Matrigel model.
Kibbey MC; Grant DS; Kleinman HK
J Natl Cancer Inst; 1992 Nov; 84(21):1633-8. PubMed ID: 1279183
[TBL] [Abstract][Full Text] [Related]
19. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
